Coffee Consumption, Myocardial Infarction and Stroke: What is the Association?

The acute effects of coffee consumption on blood glucose and it’s relationship with serum cortisol and insulin in females

This research was aimed at analyzing the acute effects of Arabica black coffee consumption on blood glucose, insulin, and serum cortisol levels, as well as determining the pharmacological effects of black coffee as an antihyperglycemic. A randomized control trial with healthy female subjects was used in this study. There were 20 volunteers in total: 9 as the control group and 11 as the trial group. The treatment included brewing 10 grams of Gayo Arabica black coffee powder with 150 ml of boiling water. Blood glucose, insulin, and cortisol levels were measured twice, before and after 60 minutes of coffee consumption. An independent sample t-test (p < 0.05), Pearson correlation test (p < 0.05), and simple linear correlation test (p < 0.05) were used to analyze the data. Blood glucose levels and serum cortisol levels decreased significantly after coffee consumption in the trial group (p = 0.002* and p = 0.001*). There was no significant negative correlation between glucose and insulin levels (r = -0.122; p = 0.721). On the other hand, there was a significant positive correlation between cortisol levels and blood glucose (r = 0.651; p = 0.002*). In conclusion, a single cup of Gayo Arabica black coffee reduces blood sugar and serum cortisol levels, but does not increase serum insulin levels. Blood glucose levels correlate positively with serum cortisol levels in healthy female.

Coffee consumption and risk of chronic disease in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study

BACKGROUND

Early studies suggested that coffee consumption may increase the risk of chronic disease.

OBJECTIVE

We investigated prospectively the association between coffee consumption and the risk of chronic diseases, including type 2 diabetes (T2D), myocardial infarction (MI), stroke, and cancer.

DESIGN

We used data from 42,659 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study. Coffee consumption was assessed by self-administered food-frequency questionnaire at baseline, and data on medically verified incident chronic diseases were collected by active and passive follow-up procedures. HRs and 95% CIs were calculated with multivariate Cox regression models and compared by competing risk analysis.

RESULTS

During 8.9 y of follow-up, we observed 1432 cases of T2D, 394 of MI, 310 of stroke, and 1801 of cancer as first qualifying events. Caffeinated (HR: 0.94; 95% CI: 0.84, 1.05) or decaffeinated (HR: 1.05; 95% CI: 0.84, 1.31) coffee consumption (≥4 cups/d compared with <1 cup/d; 1 cup was defined as 150 mL) was not associated with the overall risk of chronic disease. A lower risk of T2D was associated with caffeinated (HR: 0.77; 95% CI: 0.63, 0.94; P-trend 0.009) and decaffeinated (HR: 0.70; 95% CI: 0.46, 1.06; P-trend: 0.043) coffee consumption (≥4 cups/d compared with <1 cup/d), but cardiovascular disease and cancer risk were not. The competing risk analysis showed no significant differences between the risk associations of individual diseases.

CONCLUSION

Our findings suggest that coffee consumption does not increase the risk of chronic disease, but it may be linked to a lower risk of T2D.